Fibroblast and prostate tumor cell cross-talk: Fibroblast differentiation, TGF-β, and extracellular matrix down-regulation

Experimental Cell Research

Volumn 316, Issue 19, 2010, Pages 3207-3226

  Coulson Thomas, Vivien J ^a   Gesteira, Tarsis F ^a   Coulson Thomas, Yvette M ^a   Vicente, Carolina M ^a   Tersariol, Ivarne L S ^a   Nader, Helena B ^a   Toma, Leny ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Collagens; Cytoskeleton; Matrix metalloproteinases; Proteoglycans; Stromal reaction; Vimentin

Indexed keywords

BIGLYCAN; COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; DECORIN; FIBROMODULIN; LUMICAN; PROTEOGLYCAN; TRANSFORMING GROWTH FACTOR BETA; VERY LATE ACTIVATION ANTIGEN 5; VIMENTIN; GELATINASE B; INTEGRIN ALPHAVBETA1; INTERSTITIAL COLLAGENASE; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3; VITRONECTIN RECEPTOR;

ACTIN POLYMERIZATION; ARTICLE; CANCER CELL CULTURE; CARCINOGENICITY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL GROWTH; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR INTERACTION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN EXPRESSION; STROMA CELL; UPREGULATION; XENOGRAFT; ANIMAL; CELL COMMUNICATION; CELL MOTION; COCULTURE; CYTOSKELETON; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; MALE; METABOLISM; MOUSE; PATHOLOGY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL MOVEMENT; COCULTURE TECHNIQUES; CYTOSKELETON; DOWN-REGULATION; EXTRACELLULAR MATRIX; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; RECEPTORS, VITRONECTIN; SIGNAL TRANSDUCTION; STROMAL CELLS; TRANSFORMING GROWTH FACTOR BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958153436     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2010.08.005     Document Type: Article

References (85)

1. Nannuru K.C., Singh R.K. Tumor-stromal interactions in bone metastasis. Curr. Osteoporos. Rep. 2010 Jun, 8(2):105-113.
2. Mundy G.R. Mechanisms of bone metastasis. Cancer 1997, 80:1546-1556.
3. Chirgwin J.M., Guise T.A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit. Rev. Eukaryot. Gene Expr. 2000, 10:159-178.
4. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
5. Thalmann G.N., Rhee H., Sikes R.A., Pathak S., Multani A., Zhau H.E., Marshall F.F., Chung L.W. Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP cells. Eur. Urol. 2009.
6. Goldoni S., Iozzo R.V. Tumor microenvironment: modulation by decorin and related molecules harboring leucine-rich tandem motifs. Int. J. Cancer 2008, 123:2473-2479.
7. Morrissey C., Vessella R.L. The role of tumor microenvironment in prostate cancer bone metastasis. J. Cell. Biochem. 2007, 101:873-886.
8. Zidar N., Gale N., Kambic V., Fischinger J. Proliferation of myofibroblasts in the stroma of epithelial hyperplastic lesions and squamous carcinoma of the larynx. Oncology 2002, 62:381-385.
9. Donjacour A.A., Cunha G.R. Stromal regulation of epithelial function. Cancer Treat. Res. 1991, 53:335-364.
10. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
11. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
12. Gocheva V., Joyce J.A. Cysteine cathepsins and the cutting edge of cancer invasion. Cell Cycle 2007, 6:60-64.
13. Laufs S., Schumacher J., Allgayer H. Urokinase-receptor (u-PAR): an essential player in multiple games of cancer: a review on its role in tumor progression, invasion, metastasis, proliferation/dormancy, clinical outcome and minimal residual disease. Cell Cycle 2006, 5:1760-1771.
14. Fux L., Ilan N., Sanderson R.D., Vlodavsky I. Heparanase: busy at the cell surface. Trends Biochem. Sci. 2009, 34:511-519.
15. Peretti T., Waisberg J., Mader A.M., de Matos L.L., da Costa R.B., Conceicao G.M., Lopes A.C., Nader H.B., Pinhal M.A. Heparanase-2, syndecan-1, and extracellular matrix remodeling in colorectal carcinoma. Eur. J. Gastroenterol. Hepatol. 2008, 20:756-765.
16. Stern R. Hyaluronidases in cancer biology. Semin. Cancer Biol. 2008, 18:275-280.
17. Coussens L.M., Tinkle C.L., Hanahan D., Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
18. Leygue E., Snell L., Dotzlaw H., Hole K., Hiller-Hitchcock T., Roughley P.J., Watson P.H., Murphy L.C. Expression of lumican in human breast carcinoma. Cancer Res. 1998, 58:1348-1352.
19. Leygue E., Snell L., Dotzlaw H., Troup S., Hiller-Hitchcock T., Murphy L.C., Roughley P.J., Watson P.H. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 2000, 192:313-320.
20. Ishiwata T., Cho K., Kawahara K., Yamamoto T., Fujiwara Y., Uchida E., Tajiri T., Naito Z. Role of lumican in cancer cells and adjacent stromal tissues in human pancreatic cancer. Oncol. Rep. 2007, 18:537-543.
21. Santra M., Skorski T., Calabretta B., Lattime E.C., Iozzo R.V. De novo decorin gene expression suppresses the malignant phenotype in human colon cancer cells. Proc. Natl Acad. Sci. USA 1995, 92:7016-7020.
22. Santra M., Mann D.M., Mercer E.W., Skorski T., Calabretta B., Iozzo R.V. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 1997, 100:149-157.
23. Brezillon S., Zeltz C., Schneider L., Terryn C., Vuillermoz B., Ramont L., Perrau C., Pluot M., Diebold M.D., Radwanska A., Malicka-Blaszkiewicz M., Maquart F.X., Wegrowski Y. Lumican inhibits B16F1 melanoma cell lung metastasis. J. Physiol. Pharmacol. 2009, 60(Suppl 4):15-22.
24. 1-arrest in pancreatic cancer cell lines. Gastroenterology 2001, 121:657-667.
25. Keene D.R., San Antonio J.D., Mayne R., McQuillan D.J., Sarris G., Santoro S.A., Iozzo R.V. Decorin binds near the C terminus of type I collagen. J. Biol. Chem. 2000, 275:21801-21804.
26. Neame P.J., Kay C.J., McQuillan D.J., Beales M.P., Hassell J.R. Independent modulation of collagen fibrillogenesis by decorin and lumican. Cell. Mol. Life Sci. 2000, 57:859-863.
27. Geng Y., McQuillan D., Roughley P.J. SLRP interaction can protect collagen fibrils from cleavage by collagenases. Matrix Biol. 2006, 25:484-491.
28. Paszek M.J., Zahir N., Johnson K.R., Lakins J.N., Rozenberg G.I., Gefen A., Reinhart-King C.A., Margulies S.S., Dembo M., Boettiger D., Hammer D.A., Weaver V.M. Tensional homeostasis and the malignant phenotype. Cancer Cell 2005, 8:241-254.
29. Mundy G.R., DeMartino S., Rowe D.W. Collagen and collagen-derived fragments are chemotactic for tumor cells. J. Clin. Invest. 1981, 68:1102-1105.
30. Cooper C.R., Pienta K.J. Cell adhesion and chemotaxis in prostate cancer metastasis to bone: a minireview. Prostate Cancer Prostatic Dis. 2000, 3:6-12.
31. Bi X., Tong C., Dockendorff A., Bancroft L., Gallagher L., Guzman G., Iozzo R.V., Augenlicht L.H., Yang W. Genetic deficiency of decorin causes intestinal tumor formation through disruption of intestinal cell maturation. Carcinogenesis 2008, 29:1435-1440.
32. Chen X.D., Fisher L.W., Robey P.G., Young M.F. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. 2004, 18:948-958.
33. Desnoyers L., Arnott D., Pennica D. WISP-1 binds to decorin and biglycan. J. Biol. Chem. 2001, 276:47599-47607.
34. Guidetti G.F., Bartolini B., Bernardi B., Tira M.E., Berndt M.C., Balduini C., Torti M. Binding of von Willebrand factor to the small proteoglycan decorin. FEBS Lett. 2004, 574:95-100.
35. Inkson C.A., Ono M., Bi Y., Kuznetsov S.A., Fisher L.W., Young M.F. The potential functional interaction of biglycan and WISP-1 in controlling differentiation and proliferation of osteogenic cells. Cells Tissues Organs 2009, 189:153-157.
36. Kolb M., Margetts P.J., Galt T., Sime P.J., Xing Z., Schmidt M., Gauldie J. Transient transgene expression of decorin in the lung reduces the fibrotic response to bleomycin. Am. J. Respir. Crit. Care Med. 2001, 163:770-777.
37. Kresse H., Seidler D.G., Muller M., Breuer E., Hausser H., Roughley P.J., Schonherr E. Different usage of the glycosaminoglycan attachment sites of biglycan. J. Biol. Chem. 2001, 276:13411-13416.
38. Nili N., Cheema A.N., Giordano F.J., Barolet A.W., Babaei S., Hickey R., Eskandarian M.R., Smeets M., Butany J., Pasterkamp G., Strauss B.H. Decorin inhibition of PDGF-stimulated vascular smooth muscle cell function: potential mechanism for inhibition of intimal hyperplasia after balloon angioplasty. Am. J. Pathol. 2003, 163:869-878.
39. Tufvesson E., Malmstrom J., Marko-Varga G., Westergren-Thorsson G. Biglycan isoforms with differences in polysaccharide substitution and core protein in human lung fibroblasts. Eur. J. Biochem. 2002, 269:3688-3696.
40. Wakefield L.M., Roberts A.B. TGF-beta signaling: positive and negative effects on tumorigenesis. Curr. Opin. Genet. Dev. 2002, 12:22-29.
41. Akhurst R.J., Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol. 2001, 11:S44-S51.
42. Verona E.V., Elkahloun A.G., Yang J., Bandyopadhyay A., Yeh I.T., Sun L.Z. Transforming growth factor-beta signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Res. 2007, 67:5737-5746.
43. Sappino A.P., Schurch W., Gabbiani G. Differentiation repertoire of fibroblastic cells: expression of cytoskeletal proteins as marker of phenotypic modulations. Lab. Invest 1990, 63:144-161.
44. Santibanez J.F., Guerrero J., Quintanilla M., Fabra A., Martinez J. Transforming growth factor-beta1 modulates matrix metalloproteinase-9 production through the Ras/MAPK signaling pathway in transformed keratinocytes. Biochem. Biophys. Res. Commun. 2002, 296:267-273.
45. Johansson N., Ala-aho R., Uitto V., Grenman R., Fusenig N.E., Lopez-Otin C., Kahari V.M. Expression of collagenase-3 (MMP-13) and collagenase-1 (MMP-1) by transformed keratinocytes is dependent on the activity of p38 mitogen-activated protein kinase. J. Cell Sci. 2000, 113(Pt 2):227-235.
46. Ellenrieder V., Hendler S.F., Ruhland C., Boeck W., Adler G., Gress T.M. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int. J. Cancer 2001, 93:204-211.
47. Kuo Y.C., Su C.H., Liu C.Y., Chen T.H., Chen C.P., Wang H.S. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. Int. J. Cancer 2009, 124:2568-2576.
48. Stuelten C.H., DaCosta Byfield S., Arany P.R., Karpova T.S., Stetler-Stevenson W.G., Roberts A.B. Breast cancer cells induce stromal fibroblasts to express MMP-9 via secretion of TNF-alpha and TGF-beta. J. Cell Sci. 2005, 118:2143-2153.
49. Beacham D.A., Cukierman E. Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression. Semin. Cancer Biol. 2005, 15:329-341.
50. Olumi A.F., Grossfeld G.D., Hayward S.W., Carroll P.R., Tlsty T.D., Cunha G.R. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 1999, 59:5002-5011.
51. Shekhar M.P., Werdell J., Santner S.J., Pauley R.J., Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer Res. 2001, 61:1320-1326.
52. Orimo A., Gupta P.B., Sgroi D.C., Arenzana-Seisdedos F., Delaunay T., Naeem R., Carey V.J., Richardson A.L., Weinberg R.A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
53. Paland N., Kamer I., Kogan-Sakin I., Madar S., Goldfinger N., Rotter V. Differential influence of normal and cancer-associated fibroblasts on the growth of human epithelial cells in an in vitro cocultivation model of prostate cancer. Mol. Cancer Res. 2009, 7:1212-1223.
54. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
55. Coulson-Thomas Y.M., Coulson-Thomas V.J., Filippo T.R., Mortara R.A., da Silveira R.B., Nader H.B., Porcionatto M.A. Adult bone marrow-derived mononuclear cells expressing chondroitinase AC transplanted into CNS injury sites promote local brain chondroitin sulphate degradation. J. Neurosci. Meth. 2008, 171:19-29.
56. Massague J. TGFbeta in cancer. Cell 2008, 134:215-230.
57. Buck A., Buchholz M., Wagner M., Adler G., Gress T., Ellenrieder V. The tumor suppressor KLF11 mediates a novel mechanism in transforming growth factor beta-induced growth inhibition that is inactivated in pancreatic cancer. Mol. Cancer Res. 2006, 4:861-872.
58. Turley R.S., Finger E.C., Hempel N., How T., Fields T.A., Blobe G.C. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 2007, 67:1090-1098.
59. Sharifi N., Lechleider R.J., Farrar W.L. Transforming growth factor-beta receptor III downregulation in prostate cancer: is inhibin B a tumor suppressor in prostate?. J. Mol. Endocrinol. 2007, 39:329-332.
60. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
61. Guo Y., Jacobs S.C., Kyprianou N. Down-regulation of protein and mRNA expression for transforming growth factor-beta (TGF-beta1) type I and type II receptors in human prostate cancer. Int. J. Cancer 1997, 71:573-579.
62. Geiser A.G., Burmester J.K., Webbink R., Roberts A.B., Sporn M.B. Inhibition of growth by transforming growth factor-beta following fusion of two nonresponsive human carcinoma cell lines. Implication of the type II receptor in growth inhibitory responses. J. Biol. Chem. 1992, 267:2588-2593.
63. Park K., Kim S.J., Bang Y.J., Park J.G., Kim N.K., Roberts A.B., Sporn M.B. Genetic changes in the transforming growth factor beta (TGF-beta) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta. Proc. Natl Acad. Sci. USA 1994, 91:8772-8776.
64. Sun L., Wu S., Coleman K., Fields K.C., Humphrey L.E., Brattain M.G. Autocrine transforming growth factor-beta 1 and beta 2 expression is increased by cell crowding and quiescence in colon carcinoma cells. Exp. Cell Res. 1994, 214:215-224.
65. Kadin M.E., Cavaille-Coll M.W., Gertz R., Massague J., Cheifetz S., George D. Loss of receptors for transforming growth factor beta in human T-cell malignancies. Proc. Natl Acad. Sci. USA 1994, 91:6002-6006.
66. Markowitz S., Wang J., Myeroff L., Parsons R., Sun L., Lutterbaugh J., Fan R.S., Zborowska E., Kinzler K.W., Vogelstein B., et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 1995, 268:1336-1338.
67. Tuxhorn J.A., Ayala G.E., Smith M.J., Smith V.C., Dang T.D., Rowley D.R. Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin. Cancer Res. 2002, 8:2912-2923.
68. Ronnov-Jessen L., Petersen O.W. Induction of alpha-smooth muscle actin by transforming growth factor-beta 1 in quiescent human breast gland fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab. Invest. 1993, 68:696-707.
69. Egeblad M., Littlepage L.E., Werb Z. The fibroblastic coconspirator in cancer progression. Cold Spring Harb. Symp. Quant. Biol. 2005, 70:383-388.
70. Gulubova M., Vlaykova T. Immunohistochemical assessment of fibronectin and tenascin and their integrin receptors alpha5beta1 and alpha9beta1 in gastric and colorectal cancers with lymph node and liver metastases. Acta Histochem. 2006, 108:25-35.
71. Wei J., Xu G., Wu M., Zhang Y., Li Q., Liu P., Zhu T., Song A., Zhao L., Han Z., Chen G., Wang S., Meng L., Zhou J., Lu Y., Ma D. Overexpression of vimentin contributes to prostate cancer invasion and metastasis via src regulation. Anticancer Res. 2008, 28:327-334.
72. Zhao Y., Yan Q., Long X., Chen X., Wang Y. Vimentin affects the mobility and invasiveness of prostate cancer cells. Cell Biochem. Funct. 2008, 26:571-577.
73. Whipple R.A., Balzer E.M., Cho E.H., Matrone M.A., Yoon J.R., Martin S.S. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res. 2008, 68:5678-5688.
74. Zhao J., Dong L., Lu B., Wu G., Xu D., Chen J., Li K., Tong X., Dai J., Yao S., Wu M., Guo Y. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology 2008, 135:956-968.
75. Kim Y., Wallace J., Li F., Ostrowski M., Friedman A. Transformed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor: a mathematical model and experiments. J. Math. Biol. 2009.
76. Prahlad V., Yoon M., Moir R.D., Vale R.D., Goldman R.D. Rapid movements of vimentin on microtubule tracks: kinesin-dependent assembly of intermediate filament networks. J. Cell Biol. 1998, 143:159-170.
77. Whipple R.A., Cheung A.M., Martin S.S. Detyrosinated microtubule protrusions in suspended mammary epithelial cells promote reattachment. Exp. Cell Res. 2007, 313:1326-1336.
78. Gaggioli C., Hooper S., Hidalgo-Carcedo C., Grosse R., Marshall J.F., Harrington K., Sahai E. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat. Cell Biol. 2007, 9:1392-1400.
79. Sawada K., Mitra A.K., Radjabi A.R., Bhaskar V., Kistner E.O., Tretiakova M., Jagadeeswaran S., Montag A., Becker A., Kenny H.A., Peter M.E., Ramakrishnan V., Yamada S.D., Lengyel E. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008, 68:2329-2339.
80. Kohrmann A., Kammerer U., Kapp M., Dietl J., Anacker J. Expression of matrix metalloproteinases (MMPs) in primary human breast cancer and breast cancer cell lines: new findings and review of the literature. BMC Cancer 2009, 9:188.
81. Roy R., Yang J., Moses M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 2009, 27:5287-5297.
82. McCawley L.J., Matrisian L.M. Matrix metalloproteinases: they're not just for matrix anymore!. Curr. Opin. Cell Biol. 2001, 13:534-540.
83. Dong Z., Bonfil R.D., Chinni S., Deng X., Trindade Filho J.C., Bernardo M., Vaishampayan U., Che M., Sloane B.F., Sheng S., Fridman R., Cher M.L. Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue. Am. J. Pathol. 2005, 166:1173-1186.
84. Poincloux L., Durando X., Seitz J.F., Thivat E., Bardou V.J., Giovannini M.H., Parriaux D., Barriere N., Giovannini M., Delpero J.R., Monges G. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Surg. Oncol. 2009, 18:357-365.
85. Ohshiba T., Miyaura C., Inada M., Ito A. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br. J. Cancer 2003, 88:1318-1326.